True North Therapeutics Presents Preclinical Results Showing Potential Of TNT009 To Treat Complement-Mediated Rare Diseases

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--True North Therapeutics, a biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare diseases, presented data today from preclinical efficacy studies of TNT009 for the treatment of Cold Agglutinin Disease (CAD), a rare autoimmune hemolytic anemia, at the 2013 American Society for Hematology (ASH) International Conference in New Orleans. TNT009, the company’s lead monoclonal antibody drug candidate, was shown in preclinical studies to be a potent and specific inhibitor of the Classical Complement pathway and demonstrated the ex vivo ability to prevent Complement deposition, phagocytosis, and hemolysis of red blood cells induced by autoantibodies from CAD patients.

Help employers find you! Check out all the jobs and post your resume.

Back to news